/

QuidelOrtho Corporation

QDEL US

QDEL USQuidelOrtho Corporation

United States Composite

42.50

USD

+0.28

(+0.66%)

0.20EPS Dil.

214.67P/E

2.84BMarket Cap

QuidelOrtho Corporation

QDEL

(United States Composite)

Recent

price

42.50

P/E

ratio

214.67

div

yld

- -

ROIC.AI

Legends:

Stock price

-0.06

Beta (1.0 Market)

% total return 05/05

Stock

S&P500

YTD

-24.47

- -

-40.51

- -

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

TTM

FRC

3.69

4.02

5.48

3.97

4.82

4.71

5.18

5.30

5.75

5.86

8.23

13.75

13.09

39.45

40.35

57.50

46.82

0.43

0.59

1.10

-0.39

0.23

0.15

0.22

-0.21

-0.18

-0.42

-0.24

1.95

1.78

19.24

16.73

9.66

0.20

0.74

0.77

2.19

-0.73

0.80

-0.24

0.09

0.71

0.57

0.00

0.30

2.75

2.62

13.41

12.19

13.11

2.20

- -

-1.15

-0.60

0.48

0.10

0.31

0.46

0.67

0.45

0.29

-0.13

-0.36

1.57

3.22

22.35

39.56

33.10

32.65

2.86

3.45

4.07

-0.43

1.22

2.05

2.36

3.55

3.18

2.71

-9.08

-2.20

1.78

20.65

35.83

-10.03

-6.78

118

128

164

113

159

156

175

183

196

192

278

522

535

1,662

1,699

3,266

3,122

16.50

22.34

33.51

-11.48

8.66

5.68

3.41

-3.09

1.40

-2.32

9.38

21.09

19.51

64.03

53.91

30.00

9.36

133

208

-11

-7

-6

-14

-8

810

704

549

33.59

36.69

36.94

- -

33.53

34.40

- -

5.52

22.11

21.78

25.44

37.74

11.55

14.71

20.02

-9.94

4.81

3.21

4.21

-3.87

-3.10

-7.21

-2.94

14.20

13.63

48.76

41.46

16.80

0.42

239

210

192

203

805

1,117

568

511

147

148

377

101

129

2,617

2,451

108

119

126

113

185

200

224

245

219

201

227

426

560

1,333

1,929

4,935

4,967

11.39

14.99

25.75

- -

4.24

2.58

- -

16.32

73.92

38.56

14.81

2.39

-35.71

-92.07

517.75

- -

12.75

13.68

- -

41.74

125.76

49.88

17.77

2.11

- -

-134.91

116.76

38.85

38.80

-36.84

-48.15

- -

74.21

150.09

54.29

28.53

0.61

Capital Structure

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

ST Debt

208

207

193

LT Borrowings

2,380

2,309

2,275

LT Finance Leases

183

181

176

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

5,933

5,535

4,878

Working Capital

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

Total Current Assets

1,499

1,308

1,371

Cash, Cash Equivalents & STI

397

224

193

Accounts Receivable, Net

275

247

331

Inventories

529

542

552

Total Current Liabilities

908

790

860

Payables & Accruals

366

310

362

ST Debt

208

207

193

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

46.20%

79.07%

92.23%

Net Income, GAAP

-28.81%

-10.37%

-22.02%

Free Cash Flow

0.00%

283.15%

45.03%

Total Cash Common Dividend

- -

Total Equity

47.32%

91.54%

155.83%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

375

177

510

637

1,699

2022

1,002

613

784

867

3,266

2023

846

665

744

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

4.19

0.46

5.17

6.73

16.73

2022

11.45

0.37

0.29

0.46

9.66

2023

0.73

-0.80

-0.19

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Business: QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

Business: QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

TTM

FRC

3.69

4.02

5.48

3.97

4.82

4.71

5.18

5.30

5.75

5.86

8.23

13.75

13.09

39.45

40.35

57.50

46.82

0.43

0.59

1.10

-0.39

0.23

0.15

0.22

-0.21

-0.18

-0.42

-0.24

1.95

1.78

19.24

16.73

9.66

0.20

0.74

0.77

2.19

-0.73

0.80

-0.24

0.09

0.71

0.57

0.00

0.30

2.75

2.62

13.41

12.19

13.11

2.20

- -

-1.15

-0.60

0.48

0.10

0.31

0.46

0.67

0.45

0.29

-0.13

-0.36

1.57

3.22

22.35

39.56

33.10

32.65

2.86

3.45

4.07

-0.43

1.22

2.05

2.36

3.55

3.18

2.71

-9.08

-2.20

1.78

20.65

35.83

-10.03

-6.78

118

128

164

113

159

156

175

183

196

192

278

522

535

1,662

1,699

3,266

3,122

16.50

22.34

33.51

-11.48

8.66

5.68

3.41

-3.09

1.40

-2.32

9.38

21.09

19.51

64.03

53.91

30.00

9.36

133

208

-11

-7

-6

-14

-8

810

704

549

33.59

36.69

36.94

- -

33.53

34.40

- -

5.52

22.11

21.78

25.44

37.74

11.55

14.71

20.02

-9.94

4.81

3.21

4.21

-3.87

-3.10

-7.21

-2.94

14.20

13.63

48.76

41.46

16.80

0.42

239

210

192

203

805

1,117

568

511

147

148

377

101

129

2,617

2,451

108

119

126

113

185

200

224

245

219

201

227

426

560

1,333

1,929

4,935

4,967

11.39

14.99

25.75

- -

4.24

2.58

- -

16.32

73.92

38.56

14.81

2.39

-35.71

-92.07

517.75

- -

12.75

13.68

- -

41.74

125.76

49.88

17.77

2.11

- -

-134.91

116.76

38.85

38.80

-36.84

-48.15

- -

74.21

150.09

54.29

28.53

0.61